Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma

Ann Hematol. 2024 Jan;103(1):251-258. doi: 10.1007/s00277-023-05503-z. Epub 2023 Oct 18.

Abstract

Non-Hispanic Black patients are disproportionally affected by multiple myeloma (MM) and whether efficacy outcomes after autologous stem cell transplant (ASCT) differ by race and ethnicity remains an area of active investigation. This study included 449 patients enriched with a large proportion of non-Hispanic Black patients and sought to highlight the impact of race and ethnicity on outcomes after HDT-ASCT for patients with newly diagnosed MM. We found induction chemotherapy followed by high-dose therapy-ASCT and maintenance chemotherapy is associated with long-term PFS and OS, regardless of race or ethnicity.

Keywords: Disparities; Ethnicity; Myeloma; Race; Transplant.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Disease-Free Survival
  • Ethnicity
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / therapy
  • Retrospective Studies
  • Stem Cell Transplantation
  • Transplantation, Autologous